medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 4

<< Back Next >>

Ann Hepatol 2004; 3 (4)

In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective?

Ruelas-Villavicencio AL, Vargas-Vorácková F

Language: English
References: 41
Page: 152-159
PDF size: 83.89 Kb.


Text Extraction

Background: Despite well known worldwide differences in hepatocellular carcinoma incidence, which reflect different risk profiles, current recommendation of surveillance with ultrasound and alpha-fetoprotein twice-a-year has been restricted to cirrhotic patients. To evaluate the generalizability of this recommendation, we reviewed the clinical charts of hepatocellular carcinoma cases in a Mexican scenario. To evaluate efficiency, we performed a literature based cost-effectiveness analysis. Methods: Charts pertaining to 174 consecutive patients with histologically proven hepatocellular carcinoma, seen at a tertiary health care centre were analysed. A decision tree, based on the surveillance and recall algorithm of the European Association for the Study of the Liver was constructed. Ultrasound and/or alpha-fetoprotein, performed every six or twelve months were the diagnostic alternatives, and accurate diagnoses, direct medical costs and cost-effectiveness ratios were the outcomes of interest. Results: Male:female ratio was 1.2:1, underlying liver disease was secondary to alcohol in 44% and to hepatitis C virus in 26%, documented cirrhosis was present in 42%. Cost-effectiveness ratios for twice-a-year ultrasound and alpha-fetoprotein ranged from $303.09 to $346.22 U.S. dollars per accurate diagnosis, and for annual ultrasound from $115.86 to $116.42 U.S. dollars. Conclusions: Male gender, hepatitis C and cirrhosis were not predominant characteristics in our series. If a hepatocellular carcinoma surveillance program were to be instituted in our setting, or where patient characteristics are similar to ours, it probably should not be restricted to cirrhotic patients. Recommended performance of ultrasound and alpha-fetoprotein every six months is the least cost-effective surveillance strategy. Instead, annual ultrasound optimises diagnoses and costs.


REFERENCES

  1. Kew MC. Hepatic tumors and cysts. In: Feldman M, Sleisenger MH, Scharschmidt B, Klein S, editors. Sleisenger´s and Fordtran´s Gastrointestinal and Liver Disease. Philadelphia, PA, USA: WB Saunders; 1998: 1364-1387.

  2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona – 2000 EASL conference. J Hepatol 2001; 35: 421-430.

  3. Bruix J, Llovet JM. HCC surveillance: who is the target population? Hepatology 2003; 37: 507-509.

  4. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-280.

  5. Colombo M. Early diagnosis of hepatocellular carcinoma in Italy. A summary of a Consensus Development Conference held in Milan, 16 November 1990 by the Italian Association for the Study of the Liver (AISF). J Hepatol 1992; 4: 401-403.

  6. Trevisani F, D’Intino PE, Grazi GL, Caraceni P, Gasbarrini A, Colantoni A, Stefanini GF, Mazziotti A, Gozzetti G, Gasbarrini G, Bernardi M. Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. Cancer 1996; 77: 2223-2232.

  7. Kubicka S, Rudolph KL, Hanke M, Tietze MK, Tillmann HL, Trautwein C, Manns M. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000; 20: 312-318.

  8. Mondragon-Sanchez R, Ochoa-Carrillo FJ, Ruiz-Molina JM, Herrera-Goepfer R, Oñate-Ocaña LF, Aiello-Crocifoglio V. Carcinoma hepatocelular. Experiencia en el Instituto Nacional de Cancerología. Rev Gastroenterol Mex 1997; 62: 34-40.

  9. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207.

  10. Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, Degos F, Valla D, Belghiti J, Degott C, Terris B. Hepatocellular carcinoma occuring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000; 32: 200-204.

  11. Grando-Lemaire V, Guettier C, Chevret S, Beaugrand M, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumours liver. Groupe d´Etuce et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 508-513.

  12. Shimada M, Rikimaru T, Sugimachi K, Hamatsu T, Yamashita Y, Aishima S, Taguchi K, Tanaka S, Shirabe K, Sugimachi K. The importance of hepatic resection for hepatocellular carcinoma originating from nonfibrotic liver. J Am Coll Surg 2000; 191: 531-537.

  13. Kuper H, Ye W, Broome U, Romelsjo A, Mucci LA, Ekbom A, Adami HO, Trichopoulos D, Nyren O. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001; 34: 714-718.

  14. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-155.

  15. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Carvallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-1493.

  16. Tazawa J, Maeda M, Nakagawa M, Ohbayashi H, Kusano F, Yamane M, Sakai Y, Suzuki K. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-715.

  17. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, Virdone R, Fusco G, Grasso R, Simonetti RG. Screening for hepatocellular carcinoma in patients with Child A cirrhosis: an 8 year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21: 1029-1034.

  18. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71.

  19. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, Martinez I, Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520-527.

  20. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986; 6: 729-738.

  21. Sherman M. Alphafetoprotein: An obituary. J Hepatol 2001; 34: 603-605.

  22. Bru C, Maroto A, Bruix J, Faus R, Bianchi L, Calvet X, Ayuso C, Vilana R, Gilabert R, Rodes J. Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. Dig Dis Sci 1989; 34: 1765-1769.

  23. Angeles-Angeles A, Gamboa-Domínguez A, Velázquez-Fernández D, Muñoz-Fernández L. Hepatic fine needle aspiration biopsy. Experience in the study of hepatic masses at the Salvador Zubiran National Institute of Nutrition. Rev Invest Clin (Mex) 1994; 46: 279-285.

  24. Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E. The evaluation of fine needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol 1994; 20: 117-121.

  25. Jaray B, Turanyi E, Szalay K, Winternitz T. Ultrasound-guided fine-needle aspiration biopsy of focal liver lesions. Orv Hetil 1997; 138: 1731-1736.

  26. Nagan H. Lipiodal computerized tomography : how sensitive and specify is the technique in the diagnosis of hepatocellular carcinoma? Br J Radiol 1990; 63: 771-775.

  27. Takayasu K, Moriyama N, Muramatsu Y, Makuuchi M, Hasegawa H, Okazaki N, Hirohashi S. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. Am J Roentgenol 1990; 155: 49-54.

  28. Kim T, Murakami T, Oi H, Matsushita M, Kishimoto H, Igarashi H, Nakamura H, Okamura J. Detection of hypervascular hepatocellular carcinoma by dynamic MRI and dynamic spiral CT. J Comput Assist Tomogr 1995; 19: 948-954.

  29. LaBrecque DR. Mass lesions & neoplasia of the liver. In: Friedman SL, McQuaid KR, Grendell JH, editors. Current Diagnosis and Treatment in Gastroenterology. New York, NY, USA: McGraw-Hill Companies, Inc; 2003: 696-709.

  30. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS, Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003; 98: 2060-2063.

  31. Aguayo A, Patt YZ. Liver cancer. Clin Liver Dis 2001; 5: 479-507.

  32. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, Persson I. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2: 301-314.

  33. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglione A, Giuseppetti R. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992; 116: 97-102.

  34. Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, Mishima A, Kono K, Kimura K, Musha H, Kotota K, Okuda K. The effect of chronic habitual-alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 1982; 49: 672-677.

  35. Macias-Rodriguez MA, Rendon-Unceta P, Tejada-Cabrera M, Infante-Hernandez JM, Correro-Aguilar F, Diaz-Garcia F, Benitez-Rodriguez E, Mangas-Rojas A, Martin Herrera L. Risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Rev Esp Enferm Dig 2000; 92: 458-463.

  36. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, Wolk A, McLaughlin JK, Fraumeni JFJr. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-1477.

  37. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other site: the Paris prospective study. Diabetes Care 2001; 24: 843-849.

  38. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.

  39. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213.

  40. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.

  41. El-Serag HB. Hepatocellular Carcinoma. An epidemiologic view. J Clin Gastroenterol 2002;35:S72-78.




2020     |     www.medigraphic.com